LONDON: Abcam Plc, a global innovator in life science reagents and tools, announced the acquisition of the entire issued share capital of Marker Gene Technologies (MGT). Financial terms of the acquisition have not been disclosed and are expected to have a minimal impact on revenue and earnings in the current financial year. Following the recent…
Tag: Abcam
Abcam acquires gene editing platform and oncology product portfolio of Applied StemCell
LONDON: Abcam Plc has announced the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life science research and diagnostic markets. As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Over…